IDEAYA Biosciences Inc. (IDYA) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

IDEAYA Biosciences Inc. (IDYA)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

22.73

-0.24 (-1.04%)

At close: Jan 14, 2025, 3:59 PM

22.41

-1.39%

Pre-market Jan 15, 2025, 07:22 AM EST

undefined% (undefined)

Bid	22.34
Market Cap	1.96B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.33
PE Ratio (ttm)	-9.75
Forward PE	n/a
Analyst	Buy

Ask	25.3
Volume	954,772
Avg. Volume (20D)	894,880
Open	23.19
Previous Close	22.97
Day's Range	22.16 - 23.52
52-Week Range	22.16 - 47.73
Beta	undefined

About IDYA

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, ...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date May 23, 2019

Employees 124

Stock Exchange NASDAQ

Ticker Symbol IDYA

Website https://www.ideayabio.com

Analyst Forecast

According to 13 analyst ratings, the average rating for IDYA stock is "Buy." The 12-month stock price forecast is $53, which is an increase of 133.22% from the latest price.

Buy 92.31%

Hold 7.69%

Sell 0.00%

Stock Forecasts

Next Earnings Release

IDEAYA Biosciences Inc. is scheduled to release its earnings on Feb 18, 2025, before market opens.
Analysts project revenue of $4.54M, reflecting a 15.73% YoY growth and earnings per share of -0.61, making a 17.31% increase YoY.

Why Price Moved

2 months ago · Source

+0.34%

IDEAYA Biosciences shares are trading higher after... Unlock content with Pro Subscription

6 months ago · Source

-3.37%

IDEAYA Biosciences shares are trading lower after the company priced a $263 million public offering of 228,572 common shares and pre-funded warrants at $35 per share.

News

1 month ago · seekingalpha.com

Ideaya Biosciences: Long-Tailed Pipeline With Positive Mid-Stage Data And Huge Cash

Ideaya Biosciences' stock experienced volatility, with significant movements driven by clinical data releases and a secondary offering, but currently trades near its December levels. Ideaya's lead can...

2 months ago · businesswire.com

Biocytogen Announces IDEAYA's Nomination of Development Candidate IDE034, a Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC and Option Exercise

BEIJING & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- #ADC--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotech company focusing on the discovery of novel ant...

2 months ago · zacks.com

Wall Street Analysts Predict an 81.88% Upside in IDEAYA Biosciences (IDYA): Here's What You Should Know

The consensus price target hints at an 81.9% upside potential for IDEAYA Biosciences (IDYA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnin...

2 months ago · zacks.com

Earnings Preview: IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings Expected to Decline

IDEAYA Biosciences (IDYA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.